2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.12 Aggarwal

PP01.12 Aggarwal - Abstract

Pdf Summary

A phase II clinical trial investigated the efficacy of selinexor in patients with advanced thymoma and thymic carcinoma, rare thymic epithelial tumors. The study was conducted in the U.S., Denmark, and France, with 31 patients enrolled. Patients received selinexor twice weekly, with dose adjustments made for tolerability. Results showed a 12.5% overall response rate (ORR) in thymoma patients and a 6.7% ORR in thymic carcinoma patients. Common treatment-related adverse events included nausea, vomiting, anemia, and fatigue. Notably, 64.5% of patients required dose reductions or interruptions due to adverse events. The study concluded that selinexor demonstrated anticancer activity in advanced TETs but with low ORRs. The trials were closed early due to low ORR and slow enrollment, partially due to the impact of the COVID-19 pandemic. Overall, selinexor showed promise in treating advanced TETs, despite the need for further research to address its efficacy and tolerability.

Keywords

Phase II clinical trial

Selinexor

Thymoma

Thymic carcinoma

Rare thymic epithelial tumors

Overall response rate

Treatment-related adverse events

Dose adjustments

Anticancer activity

COVID-19 pandemic impact